leadf
logo-loader
viewThe Valens Company
(
TSX:VLNSOTCQX:VLNCF
)

The Valens Company poised for further product innovation as it receives Cannabis Research Licence from Health Canada

The human studies will be carried out at the group's huge extraction, manufacturing and testing facilities in Kelowna, British Columbia

The Valens Company -
It means the cannabinoid-based products specialist will be able to assess how its potential offerings are perceived and differentiated between each other

The Valens Company Inc (TSE:VLNS) (OTCQX:VLNCF) says it has reached a further strategic milestone with the receipt of a Cannabis Research Licence from Health Canada, which will allow it to carry out human trials to assess how its cannabis extracts, concentrates and oils are perceived by the senses.

It means the cannabinoid-based products specialist will be able to assess how its potential offerings are perceived and differentiated between each other, the firm said.

READ: The Valens Company and Verse Cannabis launch new premium vape cartridges and CBD oils for Canadian consumers

"This exciting and strategic milestone gives us the competitive advantage to further innovate and differentiate our leading oil-based product offerings," Tyler Robson, CEO at The Valens Company said in a statement.

"With this research licence, we are now able to perform sensory assessments at the product development stage to determine quality and marketability of our products to maximize potential launch success. Findings from future proprietary research initiatives will advance our understanding of cannabis preferences allowing us to continue developing premium, next-generation products that meet evolving customer and consumer needs," he added.

The human studies will be carried out at the group's huge extraction, manufacturing and testing facilities in Kelowna, British Columbia.

"This research licence not only solidifies our position as a one-stop shop for our customers by increasing our presence within their value chains, but also provides added credibility to our platform as we look to expand to new markets," noted Jeff Fellows, president of The Valens Company.

Contact the author at giles@proactiveinvestors.com

Quick facts: The Valens Company

Follow
TSX:VLNS

Price: 2.54 CAD

Market Cap: $440.23 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

The Valens Company take a large chunk of market share after acquisition of...

The Valens Company (TSX:VLNS, OTCQX:VLNCF) President Jeff Fallows joined Steve Darling from Proactive to share news about two major acquisitions the company has made that now puts them in a new tier in the cannabis sector. Fallows talks about the rationale behind the acquisition of Verse...

2 days, 22 hours ago

2 min read